Moreover, survival curve analysis revealed longer survival times for glioma patients with relatively lower PDZK1 expression than for those with high PDZK1 expression in the CGGA (mRNAseq_325), TCGA (GEPIA:LGG) and GSE30074 datasets (Figure 1F, 1G and Supplementary Figure 1). This evidence concerns the gene PDZK1 and central nervous system cancer.